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Abstract
Background When glioma patients experience long-term seizure freedom the question arises whether antiepileptic drugs 
(AEDs) should be continued. As no prospective studies exist on seizure recurrence in glioma patients after AED withdrawal, 
we evaluated the decision-making process to withdraw AEDs in glioma patients, and seizure outcome after withdrawal.
Methods Patients with a histologically confirmed low grade or anaplastic glioma were included. Eligible patients were sei-
zure free ≥ 1 year from the date of last antitumor treatment, or ≥ 2 years since the last seizure when seizures occurred after 
the end of the last antitumor treatment. Patients and neuro-oncologists made a shared decision on the preferred AED treat-
ment (i.e. AED withdrawal or continuation). Primary outcomes were: (1) outcome of the shared decision-making process 
and (2) rate of seizure recurrence.
Results Eighty-three patients fulfilled all eligibility criteria. However, in 12/83 (14%) patients, the neuro-oncologist had 
serious objections to AED withdrawal. Therefore, 71/83 (86%) patients were analyzed; In 46/71 (65%) patients it was decided 
to withdraw AED treatment. In the withdrawal group, 26% (12/46) had seizure recurrence during follow-up. Seven of these 
12 patients (58%) had tumor progression, of which three within 3 months after seizure recurrence. In the AED continuation 
group, 8% (2/25) of patients had seizure recurrence of which one had tumor progression.
Conclusion In 65% of patients a shared decision was made to withdraw AEDs, of which 26% had seizure recurrence. AED 
withdrawal should only be considered in carefully selected patients with a presumed low risk of tumor progression.
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Introduction
Low grade gliomas are a group of primary brain tumors 
supposedly developing from supportive tissue cells, such as 
oligodendrocytes and astrocytes, or neural stem cells. In the 
presence of microvascular proliferation and necrosis, these 
tumors are designated as anaplastic gliomas. A fundamental 
shift in the diagnosis of these tumors is effectuated by the 
increasing importance of molecular markers in the histopa-
thology of these tumors [1, 2].
Most patients with low grade glioma develop seizures 
during the course of their disease. In general, patients with 
low grade gliomas [World Health Organization (WHO) 
grade II] appear to have a much higher seizure incidence (up 
to 60–90%) compared to patients with anaplastic gliomas 
(WHO grade III, 40–60%) [3–6]. Epilepsy in patients with 
glioma may be difficult to treat as 15–50% of patients do not 
become seizure free despite extensive treatment with antie-
pileptic drugs (AEDs) [3, 4]. Epilepsy in patients with brain 
tumors is characterized by localization-related seizures, 
manifesting as focal seizures either with or without focal to 
bilateral tonic-clonic seizures. In clinical practice, there is 
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no doubt that glioma patients who develop seizures require 
treatment with AEDs. To achieve adequate seizure control, 
levetiracetam and valproic acid are the mostly supported 
treatment options [5], but alternative AEDs as lamotrigine, 
lacosamide, topiramate, zonisamide or pregabaline also have 
shown a favorable efficacy and toxicity profile and limited 
interactions with other drugs such as chemotherapeutic 
agents [6–9]. Still, in 20–40% of glioma patients AED side-
effects occur, such as somnolence, dizziness, fatigue, cogni-
tive disturbances, and mood or behavioral changes [5, 10]. 
Besides seizures, the tumor itself and antitumor treatments, 
the cumulative effects of AED treatment are also likely to 
contribute to cognitive dysfunction, behavioral changes and 
a decrease in quality of life [10–13]. The potential benefits 
and harms should therefore be weighted when choosing to 
start a specific AED.
Evidence exists that antitumor treatment for glioma also 
contributes to a reduction in seizure frequency; after surgical 
resection or radiotherapy, respectively 53–87% and 32–75% 
of patients with low grade glioma become seizure free [14]. 
Also chemotherapy treatment results in a ≥ 50% reduction in 
seizure frequency in 48–78% of patients [13, 15–19]. Con-
sequently, tumor-directed treatments are increasingly rec-
ognized as potentially effective options leading to seizure 
control [20].
In the light of potential side effects and costs of long-term 
AED use and the efficacy of anti-tumor treatment regarding 
seizures, the question arises whether withdrawal of AEDs 
after an interval of seizure freedom should be considered 
[5]. Based on retrospective studies, a seizure recurrence rate 
after withdrawal between 12.5 and 27% has been reported 
in patients with mostly intra-axial brain tumors [5]. Cur-
rently, it is unknown if glioma patients and their physicians 
are willing to withdraw AEDs after long-term seizure free-
dom, and more importantly, no prospective studies exist on 
the risk of seizure recurrence in glioma patients after AED 
withdrawal. Therefore, we studied both the decision-making 
process of glioma patients and their neuro-oncologists to 
withdraw or continue AEDs after long-term seizure free-
dom, as well as the rate of seizure recurrences.
Methods
Design
A prospective, observational study was conducted. Details 
on the study design can be found in the published study 
protocol [21].
Participants
Participants were recruited from January 2014 until May 
2016 from the outpatient clinic in three large tertiary refer-
ral centers for brain tumor patients in the Netherlands: 
Haaglanden Medical Center The Hague, Brain Tumor 
Center Amsterdam at VU University Medical Center 
Amsterdam and Brain Tumor Center at the Erasmus MC 
Cancer Institute Rotterdam. Consecutive patients visiting 
the outpatient clinic were screened for eligibility based 
on information in their medical charts. The inclusion 
criteria were as follows; (1) adults > 18 years of age, (2) 
histologically confirmed WHO grade II–III glioma, (3) 
history of epilepsy defined as at least one seizure, except 
for acute provoked seizures, for which treated with AEDs, 
(4) clinically and radiologically stable disease for at least 
12 months, and (5) seizure freedom for at least 12 months 
from the date of last surgery, irradiation or chemotherapy 
cycle, or seizure freedom for at least 24 months from the 
last seizure when a seizure occurred after the last antitu-
mor treatment. As no formal definition of long-term sei-
zure freedom exists in literature, the current definition (at 
least > 12 months) was based on expert opinion. In case 
patients fulfilled the inclusion criteria, first the treating 
neuro-oncologist had to decide if it was safe to withdraw 
AEDs. If not, the reason for exclusion was registered. In 
patients in whom it was considered to be safe to withdraw 
AEDs, the neuro-oncologist and patient needed to make 
a shared decision on either continuation or withdrawal 
of AEDs. Patients had to give informed consent prior to 
inclusion in the study. The medical ethical committees of 
all participating centers approved the study.
Withdrawal or continuation of AEDs
Patients were included in the withdrawal group in case 
it was decided to withdraw AEDs, or in the continuation 
group in case of any objection to withdraw AEDs. The 
reason for AED continuation was registered separately.
In the withdrawal group, each AED was tapered accord-
ing to a fixed schedule; a step-wise 50% dose reduction 
every 2 weeks. In case of using more than one AED, the 
latest added AED was withdrawn first. In the continua-
tion group, no changes were made in antiepileptic therapy. 
All participants were evaluated at 3, 6, 12 and 18 months. 
During these follow-up assessments, data were collected 
about changes in AED treatment, seizure recurrence, type 
and date of seizures, and the date of tumor progression. In 
case of seizure recurrence, dosages of AEDs were adapted 
or AEDs were (re)started according to the expertise of the 
treating neuro-oncologist. The primary outcomes were the 
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decision-making process of AED withdrawal, and the rate 
of seizure recurrence. Secondary outcomes were type of 
epilepsy at seizure recurrence, time between inclusion in 
study and seizure recurrence, and the association between 
seizure recurrence and tumor progression, WHO grade, 
time of seizure freedom before inclusion, and time since 
diagnosis.
Statistical analysis
Baseline patient characteristics and information about sei-
zure and tumor recurrence were reported using descrip-
tive statistics. Differences between groups were assessed 
with the Chi-Squared test (χ2) or Fisher’s Exact test in 
case of categorical variables. For continuous variables the 
independent T-test or Mann–Whitney U test were used, 
depending on the distribution of the variable. Statistical 
analyses were performed using SPSS version 23 (SPSS, 
Chicago, IL). All tests were exploratory, two-tailed, and 
p < 0.05 was considered to be statistically significant.
Results
Willingness to withdraw AEDs
A total of 83 patients fulfilled all eligibility criteria. Of 
these, 71 (86%) were included in the study (Fig. 1). In 12 
patients (14%) the neuro-oncologist had serious objections to 
AED withdrawal. The reported reasons for exclusion were: 
a presumed high risk of recurrent seizures due to history 
of refractory seizures (n = 3), severe cognitive dysfunction 
(n = 2), psychologically not stable enough for withdrawal 
(n = 6), and another medical indication for AED use (n = 1). 
Of the 71 patients approved for inclusion by the treating 
neuro-oncologist, a shared decision to withdraw AED(s) 
was made in 46 patients (65%) and to continue AED(s) in 
25 patients (35%). The most frequently reported reasons to 
continue AEDs reported by patients were the possibility to 
lose their driving license in case of a new seizure (n = 8), 
and fear for recurrent seizures (n = 8). Four patients reported 
both the consequences for the driving license as well as fear 
as reason to continue AED treatment, while five patients did 
not report any reason.
Fig. 1  Flowchart patients. Eli-
gibility, AED group and seizure 
recurrence
Eligible patients for inclusion
83 (100%) 
Included in study
71/83 (86%)
Withdrawal group
46/71 (65%)
Seizure free
34/46 (74%)
Progression
5/34 (15%)
Seizure(s)
12/46 (26%)
Progression
7/12 (58%)
Continuation group
25/71 (35%)
Seizure free
23/25 (92%)
Progression
2/23 (9%)
Seizure(s)
2/25 (8%)
Progression
1/2 (50%)
Excluded by neuro-oncologist
12/83 (14%)
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Patient and tumor characteristics
The baseline characteristics of the 71 included patients are 
shown in Table 1. Patients in the withdrawal and continua-
tion group were similar with respect to all clinical and soci-
odemographic variables. The mean age in the withdrawal 
group was 50 (range 24–72) years compared to 53 (range 
28–79) years in the continuation group (p = 0.24). The with-
drawal group and continuation group consisted of 24/46 
(52%) and 17/25 (68%) WHO grade II tumors, and 22/46 
(48%) and 8/25 (32%) WHO grade III tumors (p = 0.20), 
respectively. In the withdrawal group 18/46 (39%) tumors 
had loss of 1p/19q versus 11/25 (44%) tumors in the continu-
ation group (p = 0.40). In 20 patients, 15 in the withdrawal 
and 5 in the continuation group, 1p/19q status was unknown. 
Before inclusion in the study, 33/71 (46%) patients had focal 
to bilateral tonic-clonic seizures, 13/71 (18%) had focal sei-
zures, 11/71 (15%) both focal to bilateral tonic-clonic and 
focal seizures, and for the remaining patients seizure type 
was unknown (n = 14, 20%). Eleven patients (11/46, 24%) 
Table 1  Patient and tumor 
characteristics
AED antiepileptic drug, VPA valproic acid, LEV levetiracetam, LAM lamotrigine, PHT phenytoin, CBZ car-
bamazepine, LAC lacosamide
Patient and tumor characteristics AED withdrawal group
(n = 46) (%)
AED continuation group
(n = 25) (%)
Sign (p-value)
Age (mean years, range) 50 (24–72) 53 (28–79) 0.24
Hospital < 0.005
 VUmc 18 (39) 4 (16)
 HMC 18 (39) 4 (16)
 EMC 10 (22) 17 (68)
Diagnosed (mean years, range) 7.2 (3.1–19.5) 7.9 (3.8–15.7) 0.12
WHO grade glioma 0.20
 Grade II 24 (52) 17 (68)
 Grade III 22 (48) 8 (32)
LOH 1p/19q 0.40
 1p/19q codeleted 18 (39) 11 (44)
 1p/19q not codeleted 13 (28) 9 (36)
 Unknown 15 (33) 5 (20)
Type epilepsy 0.59
 Focal to bilateral tonic clonic 21 (46) 12 (48)
 Focal 10 (22) 3 (12)
 Combination 9 (20) 2 (8)
 Unknown 6 (13) 8 (32)
Duration seizure free before inclu-
sion (median years, range)
2.9 (1–12.8) 4.1 (1–20) 0.06
Tumor progression before inclusion 0.12
 No progression 35 (76) 22 (88)
 ≥ One progression 11 (24) 3 (12)
Latest anti-tumor treatment 0.25
 Surgery 6 (13) 2 (8)
 Radiotherapy 26 (57) 11 (44)
 Chemotherapy 14 (30) 13 (52)
AED use 0.57
 VPA 10 (22) 6 (24)
 LEV 27 (59) 14 (56)
 LAM 2 (4) 1 (4)
 PHT 3 (7) 0 (0)
 CBZ 3 (7) 4 (16)
 LAC 1 (2) 0 (0)
Type therapy 0.24
 Monotherapy 40 (87) 19 (76)
 Polytherapy (> 1 AED) 6 (13) 6 (24)
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in the withdrawal group had at least once tumor progression 
compared to 3 (3/25, 12%) patients in the continuation group 
(p = 0.12). Most patients used levetiracetam or valproic acid 
as AED (58% vs. 23%), with no differences between groups 
(p = 0.57).
Follow‑up withdrawal group
The median follow-up in the withdrawal group was 2.2 
(range 0.8–3.8) years (Table 2). At the end of follow-up, 
12/46 (26%) patients who withdrew AEDs had seizure recur-
rence (Fig. 1). Of the 12 patients with seizure recurrence, 8 
(67%) patients had a focal seizure, two patients (17%) had 
a focal to bilateral tonic-clonic seizure, one patient (8%) 
had a status epilepticus consisting of a focal seizure with 
impaired awareness, and one patient (8%) probably had a 
nocturnal seizure (Table 3). Seven out of 12 patients (58%) 
had seizure recurrence within 3 months after the start of 
withdrawal. In all 12 patients, AED treatment was restarted 
according to the expertise of the treating neuro-oncologist. 
Two of these patients had repeated seizures after restarting 
AED treatment; one patient had one focal seizure while the 
other patient had frequent focal seizures, even after higher 
dosages of AEDs. The patient with the status epilepticus was 
Table 2  Seizure recurrence in 
relation to tumor progression
a 7/12 with seizure recurrence had tumor progression
b 1/2 with seizure recurrence had tumor progression
Withdrawal group (N = 46) Continuation group (N = 25) p-value
Median duration follow-up (years) 2.2 (range 0.8–3.8) 1.7 (range 0.8–2.9) 0.03
Seizure recurrence 12 (26%) 2 (8%) 0.67
Tumor progression 12 (26%)a 3 (12%)b 0.12
Table 3  Patients with seizure recurrence and/or tumor progression in both study groups
OD oligodendroglioma, A astrocytoma, OA oligo-astrocytoma, II WHO grade II, III WHO grade III, mo months
Type tumor 1p/19q Group Type seizure Inclusion-sei-
zure (mo)
Seizure-progres-
sion (mo)
Inclusion-
progression 
(mo)
Seizure recurrence and progression
 OD II Codeleted Withdrawal Focal 2.5 0 2.5
 A III Intact Withdrawal Focal 13 1 14
 OA II Unknown Withdrawal Focal 5.5 18 23.5
 A II Intact Withdrawal Focal 4.5 0 4.5
 A II Intact Withdrawal Focal 2 18 20
 A II Unknown Withdrawal Focal to bilateral tonic-clonic 4 8.5 12.5
 A II Intact Withdrawal Focal 1.5 19 20.5
 OD III Codeleted Continue Focal 6 4 10
Seizure recurrence without progression
 A III Intact Withdrawal Focal 30 – –
 OD III Codeleted Withdrawal Nocturnal 3 – –
 OA III Intact Withdrawal Focal 2 – –
 OD II Unknown Withdrawal Status epilepticus 10 – –
 OA II Unknown Withdrawal Focal to bilateral tonic-clonic 21 – –
 OD II Intact Continue Focal 18 – –
Progression without seizure recurrence
 OD III Intact Withdrawal – – – 31
 OD II Unknown Withdrawal – – – 20
 OD III Unknown Withdrawal – – – 7
 OD II Codeleted Continue – – – 11
 OD III Codeleted Withdrawal – – – 26
 A II Intact Continue – – – 17
 A II Intact Withdrawal – – – 12
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admitted to the hospital for 1 day. Another patient with sei-
zure recurrence during AED withdrawal tapered the AEDs 
faster than advised.
There were no significant differences in WHO grade, time 
of seizure freedom before inclusion, or time since diagnosis 
in the group with seizure recurrence compared to the group 
without seizure recurrence (Table 3). The 1p/19q status of 
patients without seizure recurrence differed significantly 
from the patients with seizure recurrence; 44% (15/34) 
were 1p/19q co-deleted in the group without seizure recur-
rence versus 25% (3/12) in the group with seizure recurrence 
(p = 0.04).
Twenty-six percent (12/46) of patients in the withdrawal 
group showed tumor progression during the follow-up 
period. This included 7/12 patients (58%) with seizure 
recurrence. Of these, three patients had tumor progression 
within 3 months after seizure recurrence. In the other four 
patients the interval between tumor progression and seizure 
recurrence was more than 3 months (range 4–19) (Table 3). 
Progression occurred significantly more often in patients 
with seizure recurrence (7/12, 58%) than in patients without 
seizure recurrence (5/34, 15%, p = 0.006).
Follow‑up continuation group
The median follow-up was 1.7 (range 0.8–2.9) years in the 
continuation group. In this group, 12% (3/25) showed tumor 
progression. Two out of 25 (8%) patients in this group had 
seizure recurrence, which was a focal seizure in both cases. 
One of the two patients with seizure recurrence had tumor 
progression 4 months later (Table 3).
Discussion
In this study, the decision-making process of patients and 
doctors to withdraw antiepileptic drugs in clinically and radi-
ologically stable low grade and anaplastic glioma patients 
that had long-term seizure freedom (> 1 year) was studied, 
as well as the rate of seizure recurrence after AED with-
drawal. This is the first study in which the recurrence rate of 
seizures in glioma patients is evaluated prospectively. In low 
grade as well as anaplastic glioma patients with longstand-
ing stable disease, neuro-oncologists often question whether 
continuation of AED use is necessary to remain seizure free 
after years of seizure freedom. Positive outcome of drug 
withdrawal may include improvement of cognitive function-
ing and abolishment of (subtle) side-effects of AEDs such 
as tiredness, which is especially important in this socially 
active patient population [22]. Although not all patients 
were deemed eligible for inclusion by neuro-oncologists, 
we showed that the majority of the eligible patients (65%) 
were willing to withdraw AED treatment after long-term 
seizure freedom.
After a mean follow-up of 2.2 years, the recurrence rate 
of seizures after AED withdrawal was 26% (12/46). The risk 
of seizure relapse after AED withdrawal in glioma patients 
appears to be comparable with the general epilepsy popula-
tion with non-brain tumor related epilepsy [23–25]. In the 
general epilepsy population, followed for variable periods of 
time ranging from 3 months to 23 years, a recurrence rate 
of 12–66% was reported [5, 25, 26]. Predictors for seizure 
recurrence after withdrawal in the general epilepsy popu-
lation include AED polytherapy, longer duration of active 
epilepsy, having experienced seizures after the start of AED 
treatment, and having an abnormal EEG [26]. EEG testing 
was not performed in this study, as this is not common in 
brain tumor-related epilepsy. In this patient population, the 
results of EEG testing typically do not change the decision 
to alter or withdraw AEDs [27].
From this study no definite conclusions can be drawn 
whether AED withdrawal after long-term seizure freedom 
in glioma patients is advisable as the seizure recurrence rate 
is still considerable. When making a shared-decision on pos-
sible withdrawal of AEDs, the potential positive effects of 
AED withdrawal should be weighed against the risk of sei-
zure recurrence. Both neuro-oncologists and patients are, 
in varying degrees, cautious in withdrawing AEDs due to 
fear for renewed seizures and the potential consequences 
such as seizure-related injuries. The psychosocial impact 
of recurrent seizures is also large; seizures can be embar-
rassing, obstruct professional careers, make patients more 
dependent on others, and lead to a temporary loss of a driv-
ing license [26]. Indeed, the fear for seizure recurrence and 
the possible loss of their driving license were the two most 
important reasons for patients to continue AED treatment 
in our study. The data presented in this prospective study 
can be used to better inform patients and neuro-oncologists 
about the risk of seizure recurrence, helping to make well-
considered decisions.
In all but one patient, AEDs were withdrawn in line with 
the study protocol. In this single patient, who experienced 
seizure recurrence, AEDs were tapered faster than advised. 
In theory, this quick tapering might have contributed to the 
recurrence of seizures, warranting caution in the way AEDs 
are withdrawn in glioma patients. Unfortunately, one patient 
in our study was admitted to the hospital with a focal sta-
tus epilepticus. It is noteworthy that this patient fulfilled 
the eligibility criteria for inclusion. However, it appeared 
that this patient had a medical history of status epilepticus 
(twice). Based on this finding, it could be argued not to with-
draw AEDs in seizure free patients with a history of status 
epilepticus.
It is of interest that more than half of the patients with 
seizure recurrence (7/12, 58%) in the withdrawal group had 
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tumor progression during study follow-up. Those seven 
patients were a median of 6.5 years (range 3.4–13) ago diag-
nosed with a glioma and two of them had already tumor 
progression prior to inclusion in the study. Indeed, three of 
the seven patients had tumor progression within 3 months 
after seizure recurrence. In these patients, seizure recurrence 
might have been an indication for progression of the tumor 
as there is some evidence available that seizures are a sur-
rogate marker for tumor progression [28–30]. Previously, 
seizure recurrence or worse seizure control was found to 
be associated with tumor progression following first-line 
treatment [31]. Furthermore, the risk of tumor progression 
in low grade glioma patients is four times higher in case 
of seizure recurrence [32]. Considerably more patients had 
tumor progression in the withdrawal group compared to 
the continuation group. This finding may have influenced 
the risk of seizure recurrence in the withdrawal group. It is 
also possible that the study groups were not well-balanced 
with respect to risk of progression, although no significant 
differences were found in the baseline patient- and tumor-
related characteristics. Moreover, it might be that the higher 
amount of tumor progression in the withdrawal group is 
caused by the discontinuation of AED itself, as conflicting 
evidence exists that valproic acid might have an anti-tumor 
effect as well. Several retrospective studies in patients with 
glioblastoma have suggested that valproic acid moderately 
improves survival in glioma patients treated with temozo-
lomide, although a larger meta-analysis could not confirm 
this [8, 33–35]. Interestingly, within the withdrawal group, 
the subgroup with seizure recurrence had significantly more 
often tumor progression and the prognostic more unfavora-
ble intact 1p/19q status. Although based on small numbers, 
seizure recurrence after withdrawal seems to be associated 
with the absence of 1p/19q codeletion, and is also related 
to a higher risk of tumor progression within this cohort. In 
this study, the risk of seizure recurrence after withdrawal 
was not associated with WHO grade, time after diagnosis, 
or duration of seizure freedom.
Given the inclusion criteria for our study, with stability of 
disease for at least a year as a major criterium, we purposely 
left out glioblastoma patients who have a limited prognosis. 
For the non-glioblastoma patients, we think that both grade 
II and grade III patients are of interest, since both low-grade 
and anaplastic patients with a relatively long survival might 
specifically benefit from withdrawal of antiepileptic drugs.
Due to the small numbers, a multivariable analysis to 
assess which factors were independently associated with 
seizure recurrence could not be performed.
Due to ethical objections to randomize patients with 
regard to AED withdrawal, a prospective observational study 
design was chosen, including both the decision-making pro-
cess and an evaluation of seizure outcome. For the deci-
sion to withdraw AEDs, no specific decision-making model 
was used. Instead, the process depended on the preferred 
communication method of the neuro-oncologists [36, 37]. 
Although both study groups seem to be well-balanced in 
both patient- and tumor-related characteristics, a risk exists 
for confounding-by-indication due to the non-randomized 
study design, which might have influenced the results.
Although not systematically assessed, we did receive pos-
itive responses from patients about the withdrawal of their 
medication. Patients subjectively reported a better concen-
tration or mood. Nevertheless, it would have been interest-
ing to evaluate the impact of seizure recurrence on patients’ 
wellbeing, and to ask patients whether being medication-free 
outweighs experiencing a new seizure.
Conclusion
Neuro-oncologists and glioma patients are now better 
informed about the risk of seizure recurrence after AED 
withdrawal. The results presented here can be used in shared 
decision-making during consultations. Our advice would be 
to withdraw AEDs only in carefully selected patients. The 
possible negative side effects of AEDs, the effect of antitu-
mor treatment on seizure frequency, and patients’ requests 
to withdraw medication suggest that an attempt to withdraw 
AEDs can be considered in patients with low grade or ana-
plastic glioma experiencing long-term seizure freedom.
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